Weekly Recap: Fayuvi FDA approval at $3.95M and GTX-102 program halt

Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) is advancing with FDA approval and imminent shipment of Fayuvi for Sanfilippo A at a roughly $3.95M list price while simultaneously cutting costs after halting and discontinuing its GTX-102 Angelman program following Aspire’s failed endpoints.Previous W…